Federal Register / Vol. 76, No. 52 / Thursday, March 17, 2011 / Notices 14689 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA 22152; and must be 

filed no later than April 15, 2011. 

This procedure is to be conducted 

simultaneously with and independent 

of the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: March 8, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–6166 Filed 3–16–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated November 19, 2010, 

and published in the Federal Register 

on December 3, 2010, 75 FR 75496, 

Meridian Medical Technologies, 2555 

Hermelin Drive, St. Louis, Missouri 

63144, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as an importer of 

Morphine (9300), a basic class of 

controlled substance listed in schedule 

II. 

The company manufactures a product 

containing morphine in the United 

States. The company exports this 

product to customers around the world, 

including in Europe. The company has 

been asked to ensure that its product 

sold to European customers meets 

standards established by the European 

Pharmacopeia, which is administered 

by the Directorate for the Quality of 

Medicines (EDQM). In order to ensure 

that its product will meet European 

specifications, the company seeks to 

import morphine supplied by EDQM to 

use as reference standards. This is the 

sole purpose for which the company 

will be authorized by DEA to import 

morphine. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Meridian Medical Technologies to 

import the basic class of controlled 

substance is consistent with the public 

interest and with United States 

obligations under international treaties, 

conventions, or protocols in effect on 

May 1, 1971. DEA has investigated 

Meridian Medical Technologies to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: March 9, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–6165 Filed 3–16–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated November 29, 2010, 

and published in the Federal Register 

on December 9, 2010 (75 FR 76755), 

Mylan Pharmaceuticals, Inc., 781 

Chestnut Ridge Road, Morgantown, 

West Virginia 26505, made application 

by renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of the following basic 

classes of controlled substances: 

Drug Schedule 

Methylphenidate (1724) ................. II 

Oxycodone (9143) ......................... II 

Hydromorphone (9150) .................. II 

Fentanyl (9801) .............................. II 

The company plans to import the 

listed controlled substances in finished 

dosage form (FDF) from foreign sources 

for analytical testing and clinical trials 

in which the foreign FDF will be 

compared to the company’s own 

domestically-manufactured FDF. This 

analysis is required to allow the 

company to export domesticallymanufactured FDF to foreign markets. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a), 

and determined that the registration of 

Mylan Pharmaceuticals, Inc. to import 

the basic classes of controlled 

substances is consistent with the public 

interest, and with United States 

obligations under international treaties, 

conventions, or protocols in effect on 

May 1, 1971. DEA has investigated 

Mylan Pharmaceuticals, Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: March 9, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–6164 Filed 3–16–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a), Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on November 9, 2010, 

Mallinckrodt, Inc., 3600 North Second 

Street, St. Louis, Missouri 63147, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the following basic classes of controlled 

substances: 

Drug Schedule 

Tetrahydrocannabinols (7370) ....... I 

Codeine-N-oxide (9053) ................ I 

Dihydromorphine (9145) ................ I 

Difenoxin (9168) ............................ I 

Morphine-N-oxide (9307) ............... I 

Normorphine (9313) ....................... I 

Norlevorphanol (9634) ................... I 

Amphetamine (1100) ..................... II 

Methamphetamine (1105) .............. II 

Methylphenidate (1724) ................. II 

Nabilone (7379) ............................. II 

Codeine (9050) .............................. II 

Diprenorphine (9058) ..................... II 

Etorphine HCl (9059) ..................... II 


srobinson on DSKHWCL6B1PROD with NOTICES
14690 Federal Register / Vol. 76, No. 52 / Thursday, March 17, 2011 / Notices 

Drug Schedule 

Dihydrocodeine (9120) .................. II 

Oxycodone (9143) ......................... II 

Hydromorphone (9150) .................. II 

Diphenoxylate (9170) ..................... II 

Ecgonine (9180) ............................ II 

Hydrocodone (9193) ...................... II 

Levorphanol (9220) ........................ II 

Meperidine (9230) .......................... II 

Methadone (9250) ......................... II 

Methadone intermediate (9254) .... II 

Metopon (9260) ............................. II 

Dextropropoxyphene, bulk (9273) II 

Morphine (9300) ............................ II 

Oripavine (9330) ............................ II 

Thebaine (9333) ............................ II 

Opium extracts (9610) ................... II 

Opium fluid extract (9620) ............. II 

Opium tincture (9630) .................... II 

Opium, powdered (9639) ............... II 

Opium, granulated (9640) .............. II 

Levo-alphacetylmethadol (9648) ... II 

Oxymorphone (9652) ..................... II 

Noroxymorphone (9668) ................ II 

Alfentanil (9737) ............................. II 

Remifentanil (9739) ....................... II 

Sufentanil (9740) ........................... II 

Fentanyl (9801) .............................. II 

The firm plans to manufacture the 

listed controlled substances for internal 

use and for sale to other companies. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than May 16, 2011. 

Dated: March 9, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–6157 Filed 3–16–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a), Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on September 10, 

2010, Cambrex Charles City, Inc., 1205 

11th Street, Charles City, Iowa 50616, 

made application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

4-Anilino-N-Phenethyl-4-Piperidine 

(ANPP) (8333), a basic class of 

controlled substance. 

The company plans to use this 

controlled substance in the manufacture 

of another controlled substance. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than May 16, 2011. 

Dated: March 8, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–6156 Filed 3–16–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated November 18, 2010, 

and published in the Federal Register 

on December 3, 2010, (75 FR 75498), 

Agilent Technologies, 25200 

Commercentre Drive, Lake Forest, 

California 92630–8810, made 

application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the following basic classes of controlled 

substances: 

Drug Schedule 

Phencyclidine (7471) ..................... II 

1-piperidinocyclohexanecarbonitrile 

(8603).

II 

Benzoylecgonine (9180) ................ II 

The company plans to manufacture 

small quantities of the listed controlled 

substances for use in diagnostic 

products. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Agilent Technologies to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Agilent Technologies to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: March 9, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–6163 Filed 3–16–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated November 1, 2010, 

and published in the Federal Register 

on November 12, 2010, 75 FR 69464, 

Noramco Inc., 1440 Olympic Drive, 

Athens, Georgia 30601, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the following basic classes of controlled 

substances: 

Drug Schedule 

Codeine-N-Oxide (9053) .............. I 

Morphine-N-Oxide (9307) ............. I 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

Noroxymorphone (9668) .............. II 

Alfentanil (9737) ........................... II 

Sufentanil (9740) .......................... II 

Carfentanil (9743) ......................... II 

Tapentadol (9780) ........................ II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Noramco Inc., to manufacture the listed 

basic classes of controlled substances is 

consistent with the public interest at 

this time. DEA has investigated 


srobinson on DSKHWCL6B1PROD with NOTICES